{
    "2021-02-20": [
        [
            {
                "time": "",
                "original_text": "【浙商医药|孙建】周报：‘恐高’回调，坚守主线",
                "features": {
                    "keywords": [
                        "恐高",
                        "回调",
                        "坚守",
                        "主线"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "CXO产业图谱(一)：需求强劲 小分子CDMO崛起",
                "features": {
                    "keywords": [
                        "CXO",
                        "产业图谱",
                        "需求强劲",
                        "小分子CDMO",
                        "崛起"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "制药行业一周风云榜：未见开门红，CRO触底反弹，君实生物PD-1获批新适应症",
                "features": {
                    "keywords": [
                        "制药行业",
                        "开门红",
                        "CRO",
                        "触底反弹",
                        "君实生物",
                        "PD-1",
                        "新适应症"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}